Stay updated on Epacadostat Combo with Pembrolizumab in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Epacadostat Combo with Pembrolizumab in Sarcoma Clinical Trial page.

Latest updates to the Epacadostat Combo with Pembrolizumab in Sarcoma Clinical Trial page
- CheckyesterdayChange DetectedThe webpage has updated its results reporting dates, with new dates for submissions and postings, and has added specific study documents from Memorial Sloan Kettering Cancer Center.SummaryDifference3%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has been updated to reflect a new phase II study evaluating the efficacy of the IDO1 inhibitor, epacadostat, in combination with pembrolizumab for patients with metastatic and/or locally advanced grade sarcomas. Key collaborators have been listed, and the revision number has been updated.SummaryDifference54%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 5, 2025.SummaryDifference0.4%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe webpage has updated its service availability information, indicating that some NLM-NCBI services are experiencing heavy traffic, which may impact performance. Additionally, several dates have been updated, reflecting changes in the timeline for future events.SummaryDifference2%
Stay in the know with updates to Epacadostat Combo with Pembrolizumab in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Epacadostat Combo with Pembrolizumab in Sarcoma Clinical Trial page.